Form 4: Mirum Pharmaceuticals CFO Acquires Stock Options and Restricted Stock Units

Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkhot, was granted stock options and restricted stock units on January 21, 2025.

Summary

• Eric Bjerkhot, the Chief Financial Officer of Mirum Pharmaceuticals, was granted 40,000 stock options and 10,000 restricted stock units on January 21, 2025.
• The stock options have an exercise price of $47.98 and vest over a period of four years, with 1/4th vesting one year after the Vesting Commencement Date and the remainder vesting monthly over the following three years.
• The restricted stock units vest over three years, with 1/3rd vesting on each anniversary of the Vesting Commencement Date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options and restricted stock units aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common forms of compensation for executives in the pharmaceutical industry.
• Vesting schedules are typically structured to encourage long-term performance and retention, with vesting periods of three to four years being standard.
• The specific terms of the grant, such as the exercise price and vesting schedule, are generally aligned with industry norms for companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a positive sign of the company's financial health and commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, insider trading, executive compensation, Mirum Pharmaceuticals, MIRM, equity